Please login to the form below

Not currently logged in
Email:
Password:

Novartis Pharma

This page shows the latest Novartis Pharma news and features for those working in and with pharma, biotech and healthcare.

Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial

Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial

Novartis’ drug targets the ABL myristoyl pocket, which is indicated in TKI resistance and intolerance in later treatment lines of CML. ... Our ability to treat patients with TKIs changed CML care forever,” said John Tsai, head of global drug

Latest news

  • Novartis wins FDA approval for relapsing MS drug Kesimpta Novartis wins FDA approval for relapsing MS drug Kesimpta

    Last May, Novartis’ chief exec Narasimhan identified Kesimpta as one of the company’s potential blockbusters in its emerging pipeline. ... Novartis expects Kesimpta to be available in the US in early September, and is expecting regulatory approval in

  • Novartis builds its case for novel MS treatment ofatumumab Novartis builds its case for novel MS treatment ofatumumab

    Novartis’ drug demonstrated a relative risk reduction of 34% in three-month confirmed disability worsening (CDW), and 32% in six-month CDW. ... The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent

  • Novartis’ Sandoz division announces antibiotic manufacturing plan Novartis’ Sandoz division announces antibiotic manufacturing plan

    Joint investment agreed with the Austrian federal government. Novartis’ generics division Sandoz has announced plans for a joint investment to strengthen the long-term future of integrated antibiotics manufacturing in Europe. ... Novartis is committed

  • Novartis stumbles in Q2 as COVID-19 impacts sales Novartis stumbles in Q2 as COVID-19 impacts sales

    Net profit drops by 4% as pandemic hits sales. Swiss pharma company Novartis has reported a drop in its quarterly sales and profit as the COVID-19 pandemic impacts its 2020 ... However, for therapies that require hospital stays, Novartis reported a

  • Novartis reveals plans for a zero-profit COVID-19 drugs portfolio Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

    Includes 15 medicines from company's generics division. Swiss pharma company Novartis has unveiled plans to offer a portfolio of drugs to treat COVID-19 in a bid to help patients ... The portfolio builds upon Novartis’ previous $40m donation to support

More from news
Approximately 6 fully matching, plus 542 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The Swiss flagship pharma and biotech companies such as Roche, Novartis, Actelion and ACImmune tend to garner a lot of attention, but in their small home country there is a rich ... A strong pharma and biotech history and presence. Among the top five big

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    But so far, the interaction between Big Tech and Big Pharma has been limited. ... In truth, so far Big Tech has been more of a collaborator than a competitor for Big Pharma.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    It’s too early to say what style Hahn will bring to the role and its impact on the pharma sector. ... drugmaker Sanofi on 1 September last year from a prior role as head of pharma at Novartis.

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    1 trial of its lead candidate ARV-110 in prostate cancer earlier this year, ahead of rival biotechs such as C4 Therapeutics and Kymera Therapeutics as well as big pharma firms ... That’s not dampening enthusiasm for the emerging field, however, and by

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020. ... BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of new Celgene brands like

More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest appointments

  • New hires at Bristol-Myers Squibb, Acceleron and FerGene New hires at Bristol-Myers Squibb, Acceleron and FerGene

    Acceleron . Acceleron Pharma has poached Jay Backstrom (pictured right) from Celgene, where he worked as chief medical officer. ... He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his

  • New faces at Healthware Group and HRW New faces at Healthware Group and HRW

    She spent time at Novartis representing the interests of pharma, and also worked at start-up brand Headspace.

  • Novartis changes executive committee Novartis changes executive committee

    Welteverden, who was previously head of business services for Syngenta, will join Novartis’ Basel base in Switzerland. ... Klinger initially joined Novartis back in 2011 as general counsel, North America for its biopharmaceutical arm Sandoz.

  • Pfizer’s Elizabeth Barrett joins Novartis as its oncology head Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

    She succeeds Bruno Strigini who retires. Novartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland. ... Her long-time commercial pharma industry experience, marketing skills and

  • Novartis Oncology head Bruno Strigini to retire Novartis Oncology head Bruno Strigini to retire

    The head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry. ... Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements.

More from appointments
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest from PMHub

  • EPG Health EPG Health

    With an actionable reach of over a million HCPs globally, EPG Health provides customers (including most of the top 20 pharma companies) with an integrated toolset to:. ... Novartis, Orphan Europe, Philips, Pfizer, Roche, Sanofi, Takeda, UCB, Uriach,

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

  • Marketing strategy in complex environments

    Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines. ... The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment.

  • Frontera Group Frontera Group

    Dreamskin Health . Eusa Pharma. Galderma . Gedeon Richter. Genzyme. Grunenthal . Leukaemia UK. ... Novartis Pharmaceuticals. Novex Pharma. Pfizer. Shire Pharmaceuticals. UCB . Vertex Pharmaceuticals.

  • Experienced Healthcare Marketer Gareth Thurston, joins Cello Health Consulting

    Gareth has over 20 years’ experience in senior roles in a number of pharma companies, most recently at Novartis, where he spent seven years in various roles, including Brand Lead Opthalmology, ... biggest pharma companies.” Gareth will be based at

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics